FibroBiologics (FBLG) announced significant advancements in its Bone Marrow Organoid platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline. The company’s proprietary Bone Marrow Organoids have demonstrated potential in multiple therapeutic applications: Pre-IND animal trials show that Transplantation of Bone Marrow Organoids into xenografted melanoma mouse model significantly reduced tumor size. The organoids enable efficient ex vivo gene editing, allowing for swift and targeted therapeutic interventions before transplantation. FibroBiologics’ Bone Marrow Organoids can be cryopreserved, offering a scalable and readily available treatment option for bone marrow transplantation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Faces Nasdaq Delisting Notice
- FibroBiologics Reports Increased Losses Amid R&D Expansion
- Positive Outlook on FibroBiologics, Inc. Due to Strategic Positioning and Clinical Progress in Fibroblast-Based Therapies
- FibroBiologics price target lowered to $10 from $12 at H.C. Wainwright
- FibroBiologics files patent application on generating multipotent cells